@article { ISI:000276229500006,
	title = {Discovery of rifampicin as a new anti-glycating compound by matrix-assisted laser desorption/ionization mass spectrometry-based insulin glycation assay},
	journal = {European Journal of Mass Spectrometry},
	volume = {16},
	number = {2},
	year = {2010},
	month = {FEB},
	pages = {221-226},
	publisher = {IM PUBLICATIONS},
	address = {6 CHARLTON MILL, CHARLTON, CHICHESTER,, W SUSSEX PO18 0HY, ENGLAND},
	abstract = {<p>An in vitro insulin glycation assay was developed for screening glycation inhibitors. The assay involves the use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring the formation of glycated insulin. The assay is simple, rapid and amenable for high throughput screening. Using this assay we have discovered a strong anti-glycation activity for the anti-tuberculosis drug rifampicin. These results were compared with bovine serum albumin glucose fluorescence assay. In addition, the IC(50) of rifampicin was lower than that of aminoguanidine, a known anti-glycating agent, suggesting that rifampicin is a more potent glycation inhibitor.</p>},
	keywords = {AGE, aminoguanidine, antibiotic, diabetic complication, drug repositioning, IC(50)},
	issn = {1469-0667},
	doi = {10.1255/ejms.1066},
	author = {Golegaonkar, Sandeep B. and Bhonsle, Hemangi S. and Boppana, Ramanamurthy and Kulkarni, Mahesh J.}
}
